Revolutionary Tear-Based Biomarker for Early Keratoconus Detection Unveiled, ETHealthworld

New Delhi: Delhi-based biotech company Vgenomics has partnered with Dr. Shroff’s Charity Eye Hospital to validate and commercialize a tear-based biomarker, VSP-2224, for the early detection of keratoconus, a progressive eye disorder affecting the cornea.

VSP-2224, identified in tear fluid using Vgenomics’ AI-based discovery platform RgenX-LENS, may help detect the disease earlier, before visible symptoms emerge.

Clinical validation of VSP-2224 is underway. The biomarker will also be featured in OcuTear, a rapid diagnostic panel Vgenomics is developing for ocular surface diseases.

Commenting on the development, Dr Anil Tiwari said, “This partnership enables us to translate a tear-based biomarker into a clinically viable diagnostic test, with the potential to further develop it into targeted therapeutics.”

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!